Modalis Therapeutics Corporation (TYO:4883)

Japan flag Japan · Delayed Price · Currency is JPY
66.00
+12.00 (22.22%)
Apr 28, 2026, 3:30 PM JST
-14.29%
Market Cap 5.91B
Revenue (ttm) n/a
Net Income (ttm) -2.15B
Shares Out 89.55M
EPS (ttm) -27.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 40,860,400
Average Volume 3,878,120
Open 55.00
Previous Close 54.00
Day's Range 55.00 - 76.00
52-Week Range 52.00 - 119.00
Beta 0.11
RSI 66.22
Earnings Date May 8, 2026

About Modalis Therapeutics

Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. The company is developing therapies for genetic diseases using its proprietary CRISPR-GNDM an epigenome editing technology that combines dCas9. It also develops various therapeutics for muscle disorders, cardiomyopathy, and CNS disorders. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was incorpor... [Read more]

Sector Healthcare
Founded 2016
Employees 17
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4883
Full Company Profile

Financial Performance

Financial Statements

News

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass. — SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modal...

11 months ago - Financial Post